The Bacteriophage Market is experiencing a significant resurgence driven by the escalating global health crisis posed by Antibiotic-Resistant Bacteria (ARB), often termed "superbugs." Bacteriophages, or "phages," are naturally occurring viruses that are highly specific in their ability to infect and kill bacteria, making them a promising and non-antibiotic alternative for treating difficult-to-cure bacterial infections.

The way for regulatory acceptance and commercialization in the highly specialized Bacteriophage Market.

Phage therapy, first discovered alongside antibiotics, offers several advantages, including extreme specificity (targeting only harmful bacteria and preserving the beneficial microbiome), the ability to penetrate bacterial biofilms (which resist most antibiotics), and the potential to evolve alongside the bacteria to overcome resistance. While largely established in Eastern European countries, Western research is intensifying, focusing on the development of phage cocktails (mixtures of different phages) and genetically engineered phages that are strictly lytic and free from harmful genes, paving.

Related Reports